TAVR: transforming the traetment of Aortic Stenosis
IF YOU COULD SEE ME NOW: Medication Adherence Reimagined
Boston Scientific Corporation (NYSE: BSX ) announces CE Mark and European market launch of the Emerge™ PTCA[1] Dilatation Catheter. The Emerge Catheter is a next-generation pre-dilatation balloon catheter designed specifically to offer exceptional deliverability to address challenging lesions. The company plans to launch the product immediately in CE Mark countries in both Monorail® and Over-The-Wire (OTW) options. Commercial availability is expected in the U.S. and additional international markets later this year.
April 4, 2012 (Vancouver, British Columbia and Quebec City, Quebec) — Moderate-to-severe mitral regurgitation (MR) is relatively common in patients undergoing transcatheter aortic valve implantation and is associated with a doubling in risk of 30-day death, a new series suggests. Beyond this initial period, however, survival among MR patients is just as good as among patients with no MR, and MR itself is likely to improve over time, authors of a new analysis say.
El cardiólogo Valentín Fuster (Barcelona 1943), director de la Unidad de Cardiología del Centro Médico Monte Sinaí de Nueva York y presidente del Centro Nacional de Investigaciones Cardiovasculares, apeló a los cambios de conducta y a los hábitos saludables como principal estrategia para atacar lo que llamó epidemia y que en la actualidad es la primera causa de muerte en los países desarrollados: las enfermedades cardiovasculares. Fuster inauguró el simposio "Mirando al futuro", con el que la Clínica Universidad de Navarra celebra sus 50 años de existencia, ante un auditorio en el que se congregaron más de 300 médicos y cerca de 400 enfermeras, con una conferencia titulada "Transición desde la enfermedad cardiovascular a la salud (2012-2020). El reto de identificar la enfermedad subclínica".
Tuesday
Monday
Sunday
Saturday
UPDATED APPROPRIATE USE CRITERIA FOR CORONARY REVASCULARIZATION. JANUARY – FEBRUARY 2012 VOL. 41, NO. 1
The Resolute drug-eluting stent (Medtronic) yields strong performance in coronary artery disease (CAD) patients both with and without diabetes through two years of follow-up, according to results from the RESOLUTE clinical study presented by Scott W Lee, Los Angeles, USA, at a late-breaking clinical trials session at the American Association of Clinical Endocrinologists (AACE) 21stAnnual Meeting & Clinical Congress (23–27 May, Philadelphia, USA).
St Jude Medical has announced results of the FAME II trial demonstrating that patients with fractional flow reserve (FFR)-guided stenting plus the best available medical therapy had superior outcomes to those treated with medical therapy alone. Results published online in the New England Journal of Medicine (NEJM) and presented during a Hot Line session at the ESC (European Society of Cardiology) Congress 2012 revealed that use of the PressureWire (technology used to measure blood flow restriction in the coronary arteries) yielded an 86% relative risk reduction for unplanned re-admission to the hospital with urgent revascularisation in patients with stable coronary artery disease.
[+]
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos